Exact Sciences Corp

Exact Sciences Corp

Health CarePharmaceuticals & Biotechnology
  • Price (USD)78.80
  • Today's Change3.17 / 4.19%
  • Shares traded1.81m
  • 1 Year change61.51%
  • Beta1.6311
Data delayed at least 15 minutes, as of Jan 18 2019 21:00 GMT.
More ▼

Profile data is unavailable for this security.

About the company

Exact Sciences Corporation is a molecular diagnostics company. The Company focuses on the early detection and prevention of some forms of cancer. It offers a non-invasive screening test called Cologuard for the early detection of colorectal cancer and pre-cancer. Its Cologuard test is a stool-based deoxyribonucleic acid (sDNA) screening test, which utilizes a multi-target approach to detect deoxyribonucleic acid (DNA) and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. The Cologuard test is intended for the qualitative detection of colorectal neoplasia associated DNA markers and for the presence of occult hemoglobin in human stool. It focuses on the development of additional tests for other types of cancer. It is developing a blood-based biomarker test to aid in the early detection of lung cancer in individuals with lung nodules discovered through a computerized tomography (CT) or other scan.

  • Revenue in USD (TTM)398.89m
  • Net income in USD-267.84m
  • Incorporated1995
  • Employees1.27k
  • Location
    Exact Sciences Corp441 Charmany DrMADISON 53719-1234United StatesUSA
  • Phone+1 (608) 284-5700
  • Fax+1 (608) 284-5701
  • Websitehttp://www.exactsciences.com
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
EXAS:NAQ since
Biomatrica IncDeal completed18 Oct 201818 Oct 2018Deal completed19.30%--
Data delayed at least 15 minutes, as of Jan 18 2019 21:00 GMT.

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
(YOY change %)
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
(5 yr growth rate)
Tilray Inc32.71m-39.62m7.19bn313.00--38.23--219.87-0.4557-0.45570.3722.02----------------43.09---121.12--4.98-14.260.0884--62.43--0.9387------
ICON PLC2.37bn313.80m7.25bn13.25k23.30--,010.60--13.03--19.0732.2840.7313.2313.61--38.71--0.005.529.5410.4939.207.75--
Jazz Pharmaceuticals PLC1.85bn364.74m7.79bn1.21k21.772.5713.254.215.938.4630.1450.190.35312.846.881,529,640.006.967.727.398.2793.4991.7019.7120.584.166.950.34490.008.7922.53-16.154.9738.36--
Ionis Pharmaceuticals Inc579.86m63.73m7.98bn547.00113.5811.23320.4313.770.5109-0.3354.425.170.331342.2720.111,060,073.000.8521-4.011.05-4.7338.6615.422.57-12.307.96-3.010.4319--46.4637.83217.10--88.03--
Nektar Therapeutics1.25bn745.70m8.00bn509.0011.664.4710.586.403.963.967.4110.340.88231.9870.862,453,758.0052.68-12.2356.70-14.3697.8684.6359.71-28.4013.8018.600.121--86.0030.54198.66---1.78--
Sarepta Therapeutics Inc273.90m-245.02m8.21bn255.00--12.80--29.96-3.75-3.754.219.590.27620.27267.471,074,102.00-24.71-38.50-27.25-44.9891.02---89.46-424.207.83-11.740.3937--2,751.5832.8781.03--79.29--
Neurocrine Biosciences, Inc.414.27m9.93m8.30bn400.001,317.9318.55620.2520.040.06950.06954.544.940.48561.319.871,035,663.001.16-27.471.64-29.4799.01--2.40-240.421.551.540.4616--977.5124.92-1.03--48.19--
Alnylam Pharmaceuticals, Inc.91.80m-693.08m8.83bn749.00--5.68--96.14-6.96-6.950.92414.640.0605--10.20122,562.10-45.69-31.01-49.31-33.822.10---755.00-594.6710.95--0.0199--90.666.15-19.69--65.68--
EXACT Sciences Corporation398.89m-267.84m9.68bn1.27k--13.51--24.28-2.22-,579.70-25.55-45.69-27.61-49.5974.1062.70-67.15-173.0711.72-13.770.4844--167.66129.87-43.11--152.02--
Elanco Animal Health Inc3.02bn-124.50m11.52bn5.64k--2.2468.803.81-0.3554-0.26258.4114.05------535,780.10--------48.17---4.12--1.36--0.3255---0.8409---617.75------
Seattle Genetics, Inc.609.79m-162.09m11.88bn1.10k--8.63--19.48-1.10-1.103.948.530.50381.015.02554,356.40-13.39-15.66-15.63-19.3788.7989.73-26.58-29.273.31--0.00--15.3318.0010.41--22.33--
Data as of Jan 18 2019. Currency figures normalised to Exact Sciences Corp's reporting currency: US Dollar USD

Institutional shareholders

42.83%Per cent of shares held by top holders
HolderShares% Held
T. Rowe Price Associates, Inc.as of 30 Sep 201810.90m8.87%
The Vanguard Group, Inc.as of 30 Sep 201810.43m8.49%
Wellington Management Co. LLPas of 30 Sep 20187.77m6.32%
BlackRock Fund Advisorsas of 30 Sep 20184.66m3.79%
OppenheimerFunds, Inc.as of 30 Sep 20184.52m3.68%
PRIMECAP Management Co.as of 30 Sep 20183.58m2.91%
William Blair Investment Management LLCas of 30 Sep 20183.10m2.53%
Fidelity Management & Research Co.as of 30 Sep 20182.80m2.28%
JPMorgan Investment Management, Inc.as of 30 Sep 20182.53m2.06%
SSgA Funds Management, Inc.as of 30 Sep 20182.35m1.91%
More ▼
Data from 30 Sep 2018 - 30 Sep 2018Source: FactSet Research Systems Inc.
© Thomson Reuters Click for restrictions
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.